Evidence map›Paper›PMID 39845113›Full record

ReviewRSC advances2025

Exploring sesquiterpene lactones: structural diversity and antiviral therapeutic insights.

Yhiya Amen, Gehad Abdelwahab, Ahmed A Heraiz, Mahmoud Sallam, Ahmed Othman

Abstract readReview
In one paragraph

Review in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Synthesis of α-Santonin Derivatives Linked toAntibiotics (Basel, Switzerland) · 2026
    Article
  5. Article
  6. Article
  7. Antiviral Activity of Essential Oil fromMolecules (Basel, Switzerland) · 2026
    Article
  8. Article
  9. Article
  10. Frontiers in nutrition · 2026
    Article
  11. Article
  12. Article
  13. Lipophilic Substances of the Leaves and Inflorescences ofMolecules (Basel, Switzerland) · 2025
    Article
  14. Article
  15. Frontiers in pharmacology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yhiya AmenDepartment of Pharmacognosy, Faculty of Pharmacy, Mansoura University Mansoura 35516 Egypt yhiaamen@mans.edu.eg.ORCID https://orcid.org/0000-0003-2552-4567
Gehad AbdelwahabDepartment of Pharmacognosy, Faculty of Pharmacy, Mansoura University Mansoura 35516 Egypt yhiaamen@mans.edu.eg.
Ahmed A HeraizDepartment of Pharmacognosy and Medicinal Plants, Faculty of Pharmacy (Boys), Al-Azhar University Cairo 11884 Egypt.ORCID https://orcid.org/0000-0002-4829-9860
Mahmoud SallamDepartment of Pharmacognosy and Medicinal Plants, Faculty of Pharmacy (Boys), Al-Azhar University Cairo 11884 Egypt.ORCID https://orcid.org/0000-0002-0660-031X
Ahmed OthmanDepartment of Pharmacognosy and Medicinal Plants, Faculty of Pharmacy (Boys), Al-Azhar University Cairo 11884 Egypt.ORCID https://orcid.org/0000-0002-2827-7621

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sesquiterpene lactones (SLs) are a structurally diverse group of secondary metabolites primarily produced by plants, particularly within the Asteraceae family. These compounds play significant roles in plant defense and have been extensively studied for their wide range of biological activities, including antiviral, antimicrobial, anti-inflammatory, and anticancer properties. This review focuses on the biosynthesis, structure-activity relationships, and biological activities of sesquiterpene lactones, with an emphasis on their antiviral potential. SLs exert their antiviral effects by targeting viral entry, replication, and other critical stages of the viral life cycle. Notable examples include guaianolides and germacranolides, which have demonstrated promising activity against viruses such as hepatitis C, influenza, and herpes simplex. This review also emphasizes the potential of sesquiterpene lactones as promising scaffolds for antiviral drug development, positioning these compounds as key candidates in combating viral infections.

Identifiers

PMID39845113
PMCPMC11751675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.